Arrhythmias, Cardiac Clinical Trial
Official title:
Cardiotoxicity of Abiraterone in the National French Pharmacovigilance Database and in the European Clinical Trials Database (EudraCT)
Abiraterone associated with prednisone is used in prostate cancer. Abiraterone is a selective
small-molecule inhibiting cytochrome P450 17A1 (CYP17A1), a key enzyme in androgen synthesis.
CYP17A inhibition is also responsible for mineral corticosteroid related adverse events as
hypokaliemia, fluid retention, and hypertension. Primary hyperaldosteronism is associated
with cardiovascular toxicities such as atrial fibrillation and cardiac failure. Other
androgen-deprivation therapies are not associated with increased mineral corticosteroid
level.
This study investigates reports of cardiovascular toxicities for treatment including L02 (sex
hormones used in treatment of neoplastic diseases), and G03 (sex hormones) used in prostate
cancer in the French pharmacovigilance database and in the EudraCT database.
Due to its peculiar pharmacology, abiraterone is potentially associated with more cardiotoxicity as compared to other androgen-deprivation therapies. This study investigates the main characteristics of patients affected by cardiovascular side effects of which supraventricular arrhythmias (including atrial fibrillation, atrial flutter, supraventricular tachycardia), and cardiac failure imputed to drugs classified as L02, and G03 according to anatomical therapeutic chemical (ATC) classification. A causality assessment according to the World Health Organization-The Uppsala Monitoring Centre (WHO-UMC) is systematically applied. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03079726 -
Use of Device Data to Predict Frailty in Individuals
|
||
Recruiting |
NCT06014996 -
Comparison of PFA vs. RFA in Patients With Symptomatic Paroxysmal Atrial Fibrillation.
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT05404789 -
Tolerance of Centrifuge-induced Acceleration in Subjects With Diabetes Mellitus and Cardiac Arrhythmia
|
N/A | |
Recruiting |
NCT04554160 -
Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
|
||
Recruiting |
NCT04471584 -
Comparative Analysis in Detection of Atrial Arrhythmia and ECG Quality in Three Different Insertable Cardiac Monitors
|
N/A | |
Recruiting |
NCT02906189 -
Safety of Magnetic Resonance Imaging in Non-MRI Conditional Pacemakers and ICD Devices
|
N/A | |
Completed |
NCT02550340 -
Munich Study for Beer Related ECG Change Workup
|
N/A | |
Completed |
NCT02466633 -
Effect of Monitoring System Design on Response Time to Cardiac Arrhythmias
|
N/A | |
Completed |
NCT01871090 -
Remote Device Interrogation In The Emergency Department
|
N/A | |
Completed |
NCT04884100 -
enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening
|
N/A | |
Withdrawn |
NCT04556240 -
RECORD-VP: Real-time Evaluation of Cardiac Outpatient Recording Device With VitalPatch RTM
|
||
Active, not recruiting |
NCT05481359 -
AF-FLOW Registry: This Study is to Evaluate Ablamap Software in Patients Undergoing Ablation for Atrial Fibrillation.
|
||
Recruiting |
NCT05047835 -
Comparison of Prone Position and Standard Electrocardiogram in COVID-19 Patients
|
||
Not yet recruiting |
NCT05974306 -
Evaluation of a Proactive Clinical Management and Early Diagnosis of Arrhythmias in Patients With Heart Failure and Non Severely Reduced Left Ventricular Function Through a Telemonitoring System
|
N/A | |
Not yet recruiting |
NCT05957315 -
Mobile Cardiac Outpatient Telemetry for Unexplained Syncope
|
N/A | |
Completed |
NCT06260670 -
FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation
|
N/A | |
Active, not recruiting |
NCT04876963 -
HOLT-ED: Holter-monitoring in End-stage Renal Disease
|
||
Completed |
NCT04943354 -
Associations of Combinations of Single-nucleotide Polymorphisms in Women With Premature Ovarian Failure
|
N/A | |
Recruiting |
NCT03857711 -
Randomized Clinical Trial PULVAB (Prophylactic Pulmonary Veins Ablation)
|
N/A |